Novakand Pharma Acquires SVF Vaccines

Novakand Pharma has acquired SVF Vaccines AB for an undisclosed amount. SVF Vaccines AB is a biotechnology company focused on developing a novel platform for vaccines and immunotherapies.

This platform supports administration as DNA, protein-based, or RNA.

The company's initial candidates target disease areas with high unmet medical needs, specifically Hepatitis B (HBV), Hepatitis D (HDV), and coronaviruses.

These include therapeutic and prophylactic vaccines for HDV and HBV, alongside a prophylactic coronavirus vaccine.

SVF's pipeline addresses critical global health challenges.

HDV, for instance, affects approximately 12 million carriers worldwide, with increasing prevalence in the EU, and is a main cause of cirrhosis and liver cancer.

There is currently no preventive vaccine available and very limited treatment options for HDV. HBV impacts a vast population of 300 million, with SVF targeting patients already under care.

The company also aims to develop future-proof coronavirus vaccines beyond Sars-Cov2.

SVF brings experienced expertise from top researchers in viral hepatitis vaccines and immunotherapies, with a strong track record of launching "first in class" drugs at major pharmaceutical companies.

This acquisition is expected to strategically enhance Novakand Pharma's pipeline and expand its footprint in the infectious disease sector.

Integrating SVF's innovative vaccine platform and specialized expertise is anticipated to accelerate the development of critical new therapies.

The move aims to leverage SVF's advanced candidates in viral hepatitis and coronaviruses, addressing significant global health challenges.

Synergies are expected through combining Novakand's operational resources with SVF's research and development capabilities, potentially streamlining the path to market for these promising vaccine candidates.

The combined entity is positioned to advance the development of novel vaccines and immunotherapies.

This integration aims to bring new treatment and prevention options to patients worldwide, particularly in disease areas characterized by high unmet medical needs and significant commercial potential.